Embecta Corp.

NasdaqGS EMBC

Embecta Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD 225.30 M

Embecta Corp. EBITDA is USD 225.30 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -8.15% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Embecta Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 245.30 M, a -28.27% change year over year.
Embecta Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 342.00 M, a -33.93% change year over year.
Embecta Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 517.60 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: EMBC

Embecta Corp.

CEO	Mr. Devdatt Kurdikar
IPO Date	March 22, 2022
Location	United States
Headquarters	300 Kimball Drive
Employees	2,200
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Key trends

Past 5 years